Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 11/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 11/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.51 |
| ▸ | CCR6 | P51684 | 2/20 | 0.51 |
| ▸ | CCR4 | P51679 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18310052 | 0.90 | CXCR1 (0.51) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL18310049 | 0.82 | CXCR1 (0.53) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL18310053 | 0.82 | CXCR1 (0.53) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL14904733 | 0.82 | CXCR2 (0.62) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL14904744 | 0.82 | CXCR2 (0.62) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL18314630 | 0.82 | CXCR2 (0.62) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL18556270 | 0.81 | CXCR1 (0.53) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL12312383 | 0.75 | CXCR1 (0.47) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL12261967 | 0.75 | CXCR1 (0.47) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL14904732 | 0.75 | CXCR1 (0.47) | CXCR1CXCR2CXCR3CCR6CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580412-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-28 | — | — | US | disclosed |
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362403-A1 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES | CCL2, CCR1, CCL11 | CXCR1 10/4885CXCR2 9/4885CXCR3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.